Stem Cell Innovations (fka SCLL)

[gamechanger]

Pluristem Life Systems, Inc. (PLRS, New York) said on it has completed a licensing agreement and stock swap with Stem Cell Innovations, Inc. (SCLL) for marketing rights of Pluristem’s PLX I product in Asia, excluding Japan, and 3-D stem cell expansion capability. in exchange for an upfront fee of 23 million shares of Stem Cell’s common stock, milestone payments and royalties.

“This agreement represents a potential multimillion dollar recurring revenue stream,” said Pluristem CEO Zami Aberman. “We believe this collaboration will lead to several synergistic solutions, benefiting million of patients worldwide. Our 3-D technology has numerous applications that we intend to develop with Stem Cell and other companies.”

Under the terms of the stock swap, Stem Cell will exchange 27 million shares of Stem Cell’s common stock for 66 million shares of Pluristem common stock and five-year warrants to purchase 66 million shares of Pluristem common stock at an exercise price of three cents a share.

Pluristem is developing “non-personalized stem cell expansion technology products” for the potential treatment of a variety of disorders.

Stem Cell Innovations has developed human pluripotent stem cells, known as PluriCells, for use in drug discovery, toxicology, and cell therapy.

Contact (Pluristem): William Prather, 303-883-4954, [e-mail]

Contact (Stem Cell Innovations): James H. Kelly, 281-679-7900, http://www.stemcellinnovations.com